ACTA1 and neoplasm: Whereas, tumour associated immune cells (TAMS), tumour associated fibroblasts (e.g., FAP, α-SMA, FGFRs, tenascin-C and thrombospondin-1) and tumour initiating stem cells (e.g., CD133, EpCAM and aldehyde dehydrogenases), have been utilised to allow for NPPSs drug targeting within a TME [43].